Calcium antagonist isradipine improves abnormal endothelium-dependent vasodilation in never treated hypertensive patients

Objective: To examine whether middle (two months) and long-term (six months) isradipine sustained-release treatment improves endothelium-dependent vasodilation in never treated hypertensive patients. Methods: The responses of the forearm vasculature to acetylcholine (7.5, 15 and 30 mu g/min) and sodium nitroprusside (0.8, 1.6, 3.2 mu g/min) were evaluated in 12 normotensive controls (seven men and five women, aged 25 to 49 years), and in 12 hypertensives (eight men and four women, aged 20 to 47 years) at baseline and after two and six months of isradipine sustained-release treatment. Drugs were infused into the brachial artery, and forearm blood flow was measured by strain-gauge plethysmography. Results: At baseline, the response to acetylcholine was significantly lower in hypertensives vs controls: at the highest dose (30 mu g/min), forearm blood flow was 28.6+/-2.4 ml/100 mi of tissue per min in the controls vs 8.9+/-1.0 ml/100 mi of tissue per min in hypertensives (p<0.0001). Similarly, vascular resistance was significantly (p<0.0001) higher in hypertensives: 4.8+/-0.5 units (controls) vs 15.1+/-1.7 units (hypertensives). After isradipine treatment, the forearm blood flow in hypertensive patients changed from 8.9+/-1.0 ml/100 mi of tissue per min to 16.0+/-1.2 ml/100 mi of tissue per min (two months; p<0.0001) and 15.2+/-1.4 ml/100 mi of tissue per min (six months; p<0.0001). Isradipine treatment did not modify the vasodilating effect of sodium nitroprusside. Conclusions: Our data demonstrate for the first time that the calcium antagonist isradipine improves acetylcholine-induced vasodilation in hypertensives. (C) 1999 Elsevier Science B.V. All rights reserved.